| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
11 companies
Gsk Plc serves as a 10% Owner at LYEL and has filed Form 4s across 11 companies. Across recent SEC filings that breaks down to 14 buys and 5 sells. Those positions are worth an estimated $568.5M at current prices.
Historically, Gsk Plc's trades have earned a below-average insider score of 42/100 across 5 rated trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -3.0%.
The biggest single holding is WVE (~$346.7M) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 7,561,930 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2017 | SPRO Spero Therapeutics, Inc. | 10% Owner | Buy | 428,571 | $14.00 | $5,999,994.00 | +30.1% | |
| Oct 24, 2016 | CRSP Crispr Therapeutics AG | 10% Owner | Buy | 66,500 | $14.00 | $931,000.00 | +2.1% | |
| Mar 14, 2016 | TBPH Theravance Biopharma, Inc. | 10% Owner | Buy | 1,301,015 | $0.00 | - | +15.6% | |
| Oct 7, 2015 | TBPH Theravance Biopharma, Inc. | 10% Owner | Buy | 44,574 | $0.00 | - | +0.5% | |
| Aug 7, 2015 | INVA Innoviva, Inc. | 10% Owner | Buy | 245,828 | $0.00 | - | +0.8% | |
| May 11, 2015 | INVA Innoviva, Inc. | 10% Owner | Buy | 85,579 | $0.00 | - | +0.3% | |
| Mar 2, 2015 | INVA Innoviva, Inc. | 10% Owner | Buy | 92,674 | $0.00 | - | +0.3% |